Surgery – Radioactive substance applied to body for therapy – Radioactive substance placed within body
Reexamination Certificate
2011-01-25
2011-01-25
Marmor, II, Charles A (Department: 3735)
Surgery
Radioactive substance applied to body for therapy
Radioactive substance placed within body
Reexamination Certificate
active
07874975
ABSTRACT:
Compositions, articles, and methods for treating and imaging vulnerable plaque and other inflamed regions in a patient rely on delivery of a conversion electron emitting source (CEES) to a body location. The CEES may be delivered by coupling to a substance which preferentially binds to vulnerable plaque or other inflammatory marker. Alternatively, the CEES can be delivered on a catheter, scaffold, or other device.
REFERENCES:
patent: 4647445 (1987-03-01), Lees
patent: 4660563 (1987-04-01), Lees
patent: 4877599 (1989-10-01), Lees
patent: 4937067 (1990-06-01), Lees
patent: 5216130 (1993-06-01), Line et al.
patent: 5225181 (1993-07-01), Srivastava et al.
patent: 5292938 (1994-03-01), Mease et al.
patent: 5334729 (1994-08-01), Mease et al.
patent: 5428156 (1995-06-01), Mease et al.
patent: 5429133 (1995-07-01), Thurston et al.
patent: 5510466 (1996-04-01), Krieger et al.
patent: 5639879 (1997-06-01), Mease et al.
patent: 5711931 (1998-01-01), Dean et al.
patent: 5726153 (1998-03-01), Lees et al.
patent: 5783169 (1998-07-01), Sweet et al.
patent: 5811814 (1998-09-01), Leone et al.
patent: 5968477 (1999-10-01), Kasina et al.
patent: 6171577 (2001-01-01), Kasina et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6500108 (2002-12-01), Sorensen et al.
patent: 6517810 (2003-02-01), Srivastava et al.
patent: 6869590 (2005-03-01), Edwards et al.
patent: 7238340 (2007-07-01), McBride et al.
patent: 2003/0082105 (2003-05-01), Fischman et al.
patent: 2003/0152513 (2003-08-01), Blankenberg et al.
patent: WO 89/10760 (1989-11-01), None
patent: WO 02/098285 (2002-12-01), None
Birchler et al, “Selective Targeting And Photocoagulation of Ocular Angiogenesis Mediated by a Phage-Derived Human Antibody Fragment,”Nat. Biotechnol. Oct. 1999;17(10):984-988.
Burrone et al., “Electrical Resonance and Ca2+ Influx in the Synaptic Terminal of Depolarizing Bipolar Cells from the Goldfish Retina,”J Physiol. 1997;505:571-584.
Carnemolla et al., “Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain,”Int J Cancer. Nov. 4, 1996;68(3):397-405.
D'Arceuil et al. “99m Tc Annexin V imaging of neonatal hypoxic brain injury,”Stroke2000; 31:71-75.
Demos et al., “ In-Vitro Targeting of Antibody-Conjugated Echogenic Liposomes for Site Specific Ultrasonic Image Enhancement,”J. Pharm. Sci. 1997, 86(2):167-171.
Dinkelborg et al., “Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative,”J Nucl Med. 1998;39(10):1819-1822.
Elmaleh et al., “Rapid Noninvasive Detection of Experimental Atherosclerotic Lesions with Novel 99mTc-Labeled Diadenosine Tetraphosphates,”Proc. Natl. Acad. Sci. USA, 1998, 95:691-695.
Fadok et al., “A Receptor for Phosphatidylserine Specific Clearance of Apoptotic Cells,”Nature2000; 405:85-90.
Gidon-Jeangirard et al. “Annexin V Counteracts Apoptosis While Inducing Ca(2+) Influx in Human Lymphocytic Cells,”Biochem Biophys Res Commun., Nov. 1999; 265(3):709-715.
Gidon-Jeangirard et al. “Annexin V Delays Apoptosis While exerting An External Constraint Preventing the Release of CD4+ and PrPc+ Membrane Particles in a Human T Lymphocyte Model,”Journal of Immunology1999; 162(10):5712-5718.
Halin et al., “Enhancement of the Antitumor Activity of Interleukin-12 by Targeted Delivery to Neovasculature,”Nat Biotechnol. Mar. 2002;20(3):264-9.
Halin et al., “Tumor-Targeting Properties of Antibody-Vascular Endothelial Growth Factor Fusion Proteins,”Int J Cancer. 2002;102(2):109-116.
Hammill et al. “Annexin V Staining Due to Loss of Membrane Asymmetry Can Be Reversible and Precede Commitment to Apoptotic Death,”Exp Cell Res., Aug. 25, 1999;251(1):16-21.
Kolodgie et al., “Targeting of Apoptotic Macrophages and Experimental Atheroma with Radio Labeled Annexin V: A Technique With Potential For Noninvasive Imaging of Vulnerable Plaque.”Circulation, Dec. 2003; 108(25):3134-3139.
Leese et al. “Imaging Human Atherosclerosis with 99mTc-Labeled Low Density Lipoproteins,” (1998) Arteriosclerosis 8:461-470.
Matter et al., “Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin,”Circ Res. 2004;95:1225-1233.
Narula et al. “Transient Sarcolemmal Phosphatidylserine Expression as a Marker of Brief Ischemia: An Evaluation by 99m Tc-Annexin V Imaging,”Journal of Nuclear Medicine2004;41:Suppl.p. 173-174P.
Narula et al., “Noninvasive Localization of Experimental Atherosclerotic Lesions With Mouse/Human Chimeric Z2D3 F(ab') 2 Specific for the Proliferating Smooth Muscle Cells of Human Atheroma,”Circulation, 1995, 92: 474-484.
Neri et al., “Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform,”Nat Biotechnol. Nov. 1997;15(12):1271-1275.
Nilsson et al., “Targeting Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogensis, Mediates the Infarction of Solid Tumors in Mice,”Cancer Res. 2001;61:711-716.
Pini et al., “Design and Use of a Phage Display Library. Human Antibodies with Subnanomolar Affinity Against a Marker Of Angiogensis Eluted from a Two-Dimensional Gel,”J Biol Chem. 1998;21769-21776.
Russo-Marie, “Annexin V and Phospholipid Metabolism,”Clin Chem Lab Med, Mar. 1999;373(3):287-291.
Stratton et al., “Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi,”Circulation1995, 92:3113-3121.
Strauss et al. “Radioimaging to Identify Myocardial Cell Death and Probably Injury,”Lancet2000; 356:180-181.
Vallabhajosula et al.,“ Atherosclerosis: Imaging Techniques and the Evolving Role of Nuclear Medicine,”J. Nucl. Med., 1997, 38:1788-1796.
Viti et al., “Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis,”Cancer Res., Jan. 15, 1999;59:347-352.
Winter et al, “Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis with Alpha(v)beta3-Integrin-Targeted Nanoparticles,”Circulation. 2003;108:2270-2274.
Zwaal et al., “Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells,”Blood, Feb. 1997, 89(4):1121-1132.
European Search Report and Opinion of EP Application No. 06787437.0, mailed Aug. 24, 2009, 5 pages total.
Bode, “Characterization of Type I and Type III Collagens in Human Tissue,” [Dissertation] Chapter 2.3, University of Oulu, Finland, Feb. 2000, 76 pages total.
Lammi et al., “Site-specific immunostaining for type X collagen in noncalcified articular cartilage of canine stifle knee joint,” Bone. Dec. 2002;31(6):690-696.
Fuster et al., “Atherothrombosis and High-Risk Plaque,”J Am Coll Cardiol, 2005; 46:937-954.
Final Office Action of U.S. Appl. No. 11/534,847, mailed Jul. 28, 2010, 9 pages total.
Sigma-Aldrich, “Monoclonal Anti- Collagen Type III, Clone FH-7A Mouse Ascites Fluid Datasheet”, [Product Information], Jul. 2005, Retrieved from the Internet: <<http://www.sigmaaldrich.com/sigma/datasheet/c7805dat.pdf.>>.
Srivastava et al, “Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies,”Nucl Med Biol1991;18:589-603.
Srivastava et al., “Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor immunotherapy,”Int J Pharmacog1995; 33:92-101.
Srivastava et al., “Reactor production of high-specific activity tin-117m for bone pain palliation and bone cancer therapy,”J Nucl Med, 2004; 45: 475P.
Srivastava et al., “Recent advances in radionuclide therapy,”Sem Nucl Med2001; 31: 330-341.
Srivastava, “Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy,”
Chronos Nicolas
Gonzales Gilbert R.
Clear Vascular, Inc.
Hopkins Christine D
Marmor II Charles A
Townsend and Townsend / and Crew LLP
LandOfFree
Methods and compositions for treating luminal inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating luminal inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating luminal inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707285